2022 Latest 100% Exam Passing Ratio - RAC-US Dumps PDF
Pass Exam With Full Sureness - RAC-US Dumps with 100 Questions
NEW QUESTION 28
SOPs for preventive and corrective actions MUST include the procedure to eliminate which of the following?
- A. Late and/or incorrect deliverables
- B. Inadequate training
- C. Causes of non-conformities
- D. Adverse environmental impacts
Answer: C
NEW QUESTION 29
A global company is developing a sophisticated implantable medical device that is coated with antibiotics and biologics to enhance its efficacy.
The product is marketed in Country X.
where it is regulated as a medical device.
The same product, without the antibiotics and biologics, is marketed as a medical device in Country Y.
The company is proposing to start marketing the coated device in Country Y.
Which regulatory approach should the company propose?
- A. Submit the product as a medical device in Country Y as the product is already marketed in Country X as a medical device.
- B. Apply for review of the additional part of the product as a pharmaceutical product in Country
- C. Examine decisions made about similar products in Country Y to propose the classification of the product.
- D. Submit the product for review as a pharmaceutical product in Country Y.
Answer: B
NEW QUESTION 30
Which of the following is an example of an acceptable statement for an advertisement of an approved arthritis medication?
- A. "Product X is a guaranteed cure for arthritis."
- B. "Product X is effective for the treatment of arthritis."
- C. "Product X is safe for arthritis and without side effects."
- D. "Product X is effective in all patients with arthritis."
Answer: B
NEW QUESTION 31
In a distribution contract for high-risk medical devices, which of the following regulatory requirements is the MOST important for the distributor?
- A. Local reimbursement requirements
- B. Training program for sales people
- C. Service operation procedures
- D. Written procedure for product traceability
Answer: B
NEW QUESTION 32
A company is developing a line of products for which no ISO standard of performance is available. As a result, the company wishes to propose developing such a standard. Whom should the company contact in order to start the development of the new standard?
- A. The country's regulatory authority
- B. The ISO technical committee in charge of the area
- C. The ISO national member body
- D. The ISO Secretariat
Answer: C
NEW QUESTION 33
Which analysis method is MOST appropriate to prioritize risk and monitor the effectiveness of risk control activities for a medical device?
- A. Quality by design analysis
- B. Failure modes, effects, and criticality analysis
- C. Fishbone analysis
- D. Fault tree analysis
Answer: B
NEW QUESTION 34
A regulatory affairs professional is asked to review and update regulatory affairs SOPs.
Which aspect of the SOP Is MOST important to consider?
- A. Revision history
- B. Relevance to regulations
- C. Scope and level of detail
- D. Expiration date
Answer: B
NEW QUESTION 35
A company establishes a new medical device indication for its consumer disposable products. The regulatory affairs professional is asked to give a 30-minute training session on these products to sales representatives. Which of the following subjects is the MOST important to discuss?
- A. Regulatory application summary
- B. Safety-related reporting
- C. Risk management process
- D. Labeling
Answer: D
NEW QUESTION 36
A regulation change is imminent and may require further non-clinical testing on a product currently in Phase III clinical trials. What is the most appropriate action to take FIRST?
- A. Obtain a copy of the proposed regulation and analyze the impact.
- B. Consult with the company's legal department regarding options.
- C. Inform the company's senior management and arrange an emergency meeting
- D. Arrange for additional testing of the product at the testing facility.
Answer: A
NEW QUESTION 37
One month prior to the anticipated approval date for your product, the marketing application that you submitted to a major regulatory authority has become the subject of an advisory committee meeting of experts convened by the regulatory authority. The advisory committee members unanimously vote not to approve your product because of a safety concern. Two days after the advisory committee meeting, the regulatory authority requests additional information to support the safety of your product. Assuming you have no additional data to provide, which of the following would be your MOST appropriate response to the regulatory authority's request?
- A. "We have no additional information to provide at this time because we have already provided everything needed to support our product's approval."
- B. "We disagree with the advisory committee's decision because the committee neglected the thorough safety analysis that we provided."
- C. "We have no additional information to provide at this time, but we can perform an additional analysis for a specific safety concern, if necessary."
- D. "Given the advisory committee's unanimous decision, we know that the product will not be approved, and additional data will not make any difference."
Answer: C
NEW QUESTION 38
A company is developing a novel drug to combat AIDS. The preliminary results are very promising and include instances of complete remission. The company has been granted patents in multiple countries for the drug. The regulatory affairs professional is asked to prepare a brief report concerning potential problems for marketing of the product worldwide. Which of the following is the MOST important consideration to discuss?
- A. International import and export regulations
- B. The time frame in which the patent will expire
- C. Doha Declaration in the TRIPS Agreement
- D. The stability of the drug in all zone conditions
Answer: D
NEW QUESTION 39
As part of the regulatory strategy for companies intending to manufacture a psychotropic product, which of the following approvals should be received FIRST?
- A. Export license
- B. Import license
- C. Site license
- D. Product license
Answer: C
NEW QUESTION 40
At a recent scientific meeting, Company Y had two booths:
* At one booth, Company Y provided brochures on a completed Phase II study.
* In an adjacent booth, Company Y's sales professionals were promoting one of Company
Y's marketed products.
A regulatory affairs-professional at Company X sends a letter to a counterpart at Company
Y requesting that Company Y stop this practice in the future and demanding a formal response to the letter. How should the regulatory affairs professional at Company Y BEST respond?
- A. Acknowledge receipt of the letter in a written response but do nothing further.
- B. Inform the local regulatory authority of the letter and discuss how to respond.
- C. Inform Company X that it has no right to send such a letter and do nothing further.
- D. Inform the legal department of the letter and discuss how to respond.
Answer: D
NEW QUESTION 41
The manufacturer of an API was changed from Company X to Company Y during the late stage of a new drug development. Despite differences in the manufacturing processes of the companies, both APIs meet the current specifications. Which is the MOST appropriate information to include in the final submission documents?
- A. Information deemed appropriate by the regulatory authority
- B. The process information and analytical result of Company X API
- C. The process information and the comparative analytical result of APIs from both companies
- D. The process information and analytical result of Company Y API
Answer: C
NEW QUESTION 42
A manufacturer is involved in a recall event process for a plasma-derived product. From which stage should the manufacturer be able to trace back the product?
- A. Product distribution
- B. Plasma fractionation
- C. Plasma pooling
- D. Individual plasma donation
Answer: A
NEW QUESTION 43
An inspection of a manufacturing site determines that a number of manufacturing changes have been implemented without obtaining the necessary regulatory clearance. Which of the following actions should the regulatory affairs professional complete FIRST?
- A. Stop product manufacturing.
- B. Review the stability data for the changes.
- C. Establish validation procedures.
- D. Assess the impact of the changes.
Answer: A
NEW QUESTION 44
Which of the following statements regarding export regulations for an approved product is CORRECT?
- A. The product must not be sold or offered for sale in domestic commerce.
- B. The product must not be labeled on the outside of the shipping package that it is intended for export.
- C. The product must not be in conflict with the laws of the country to which it is intended for export.
- D. The product must not be in accord with the specifications of the foreign purchaser.
Answer: C
NEW QUESTION 45
......
Verified RAC-US dumps Q&As - 100% Pass from Prep4away: https://www.prep4away.com/RAPS-certification/braindumps.RAC-US.ete.file.html
Pass RAC-US Exam in First Attempt Guaranteed 2022 Dumps: https://drive.google.com/open?id=1Oh8kwF-iZ_evjMRbMdjjLf4mOPZExjya